Clinical Trials Browser

Not yet recruiting × OTHER × fludarabine × Clear all

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT07164469 2026-03-11

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07444632 2026-03-11

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

Phase 1 Not yet recruiting

Hodgkin Disease

NCT05565105 2026-03-03

CD34+ Transplants for Leukemia and Lymphoma

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07441967 2026-03-02

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Phase 2 Not yet recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT07416682 2026-02-25

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Phase EARLY_PHASE1 Not yet recruiting

High-risk Plasma Cell Neoplasms

NCT07428993 2026-02-24

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Phase 2 Not yet recruiting

Osteosarcoma

NCT07428486 2026-02-23

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

Phase 1 Not yet recruiting

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07367685 2026-01-26

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07358260 2026-01-22

B7-H3.CD28Z.CART in Solid Tumors

Phase 1 Not yet recruiting

Neuroblastoma

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06027983 2025-09-23

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

Phase 1/2 Not yet recruiting

BreastOther solid neoplasm

HER2+ Advanced Breast Cancer

NCT06698744 2025-09-23

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT06986434 2025-09-03

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Phase EARLY_PHASE1 Not yet recruiting

Recurrence, Neoplasms, Plasma Cell

NCT07052422 2025-07-04

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Phase 2/3 Not yet recruiting

Older Patients

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06939270 2025-04-22

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

Hypoxia

NCT06825455 2025-02-13

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT06613035 2024-09-25

Twice-per-weekSelinexor, 2 Days Melphalan

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06472479 2024-06-28

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Phase NA Not yet recruiting

Multiple Myeloma

NCT06297772 2024-06-04

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06385808 2024-04-26

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Phase NA Not yet recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05303727 2022-07-01

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2 Not yet recruiting

Neuroblastoma